聖邦股份(300661.SZ):擬設江陰聖邦微電子 建設集成電路設計及測試項目
格隆匯10月20日丨聖邦股份(300661.SZ)公佈,公司於2021年10月20日召開第四屆董事會第二次會議,審議通過了《關於公司擬簽署<投資協議>暨對外投資設立子公司的議案》,公司擬與江陰高新技術產業開發區管理委員會簽署《投資協議》,並在江陰高新技術產業開發區內投資設立全資子公司江陰聖邦微電子有限公司(暫定名,最終以工商行政管理部門核定名稱為準)作為項目實施主體,建設集成電路設計及測試項目,該項目總投資金額約人民幣3億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.